Description
Dacetuzumab is a humanized monoclonal antibody targeting the CD40 antigen, which is highly expressed on most B-lineage hematologic malignancies including multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. CD40 is also found on many types of solid tumors, including bladder, renal and ovarian cancer and on cells that play a role in immunologic disorders.

Status
Dacetuzumab is currently in four phase Ib clinical trials in combination with standard regimens for non-Hodgkin lymphoma and multiple myeloma. Dacetuzumab has orphan drug designation from the FDA for multiple myeloma and chronic lymphocytic leukemia.